
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Dr. Maurie Markman sits down with Dr. Vincent T. DeVita, one of the most influential researchers and physicians in the cancer care arena.
Dr. Maurie Markman sits down with Dr. Vincent T. DeVita, one of the most influential researchers and physicians in the cancer care arena.





